Cathie Wood is making a massive bet on gene editing, pouring $5.4 billion into companies like Beam Therapeutics while selling ...

Alloy Therapeutics today announced the appointment of Christian Cobaugh, Ph.D., as Chief Executive Officer of Alloy Genetic ...

In the latest close session, CRISPR Therapeutics AG (CRSP) was up +2.58% at $55.16. This change outpaced the S&P 500's 0.64% gain on the day. Elsewhere, the Dow saw an upswing of 1.23%, while the tech ...

Management of mitochondrial-related heart disease relies on multidisciplinary care and symptom control, as targeted gene-editing therapies are limited.

Tiny, sun-powered organisms found in freshwater pools could soon fuel Hawaiʻi’s sustainable future, according to researchers ...

Since 2019, three disease-specific therapies have been approved to treat patients with ATTR-CM. The first was Pfizer’s Vyndamax (tafamidis) in May 2019, which was approved for both wild type and ...

An updated edition of the Nov. 18, 2025, article. Genomics is a broad and detailed study of genomes (an organism’s complete set of deoxyribonucleic acid or DNA). Recent scientific advances in this ...

As CRISPR moves from lab success to real-world medicine, 2026 will test whether these revolutionary gene-editing therapies ...

A patient death in a CRISPR trial halts gene editing studies, raising critical safety questions. What this means for the ...

Cell-surface proteins are critical therapeutic targets and are vital to cellular communication, signaling, and homeostasis. However, developing high-affinity probes such as aptamers against these ...

Tuesday’s market has seen swings in various stocks based on news and other factors. Today, stocks like Micron Technology and Lam Research are rallying, while stocks like Applovin and Tesla Motors are ...

Alloy Therapeutics has appointed Christian Cobaugh, Ph.D., as Chief Executive Officer of Alloy Genetic Medicines.